JT
ELVN icon

Jupiter Topco’s Enliven Therapeutics ELVN Stock Holding History

Jupiter Topco’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6M Buy
+604,122
New +$25.6M 0.01% 556

Other funds holding ELVN

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco's ELVN Position: Q2 2026 in Review

Jupiter Topco opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 604,122 shares worth $30.6M. The stake represents 0.01% of the portfolio and ranks #556 among its holdings.

189 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jupiter Topco held 604,122 shares of Enliven Therapeutics worth $30.6M as of Q2 2026.
  • Enliven Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Enliven Therapeutics made up 0.01% of Jupiter Topco's portfolio in Q2 2026, its #556 holding.
  • 189 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.